News
Helium Special Situations increases interest in Scancell
17th November 2011Holdings in Company
The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100
Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
XCAP Securities Plc - Broker
Jon Belliss/ Adrian Kirk
+44 (0) 207 101 7070
Press coverage
- Richard Goodfellow - why we want to work with patient advocacy groups
- What I Learned From the CEO of an Immunotherapy Start-Up
- Biotech blockbusters
- Is this the pioneering DNA vaccine we've been waiting for?
- Electric jab in your arm that fights skin cancer
- Finanz und Wirtschaft 5th June 2013
- Finanz und Wirtschaft 12th June 2013
- ECOreporter 14th August 2013
- Scancell And OncoSec looking good with melanoma immunotherapies
- Why checkpoint inhibitors need help June 2014
Webcasts, Interviews and Media Coverage
Scancell to raise up to £8mln to develop its three main drug candidates
Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.
A placing and subscription at 12 pence a share will account for £6mln of the total.
The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.
Wed, 18 Apr 2018 12:18:00
Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs
In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline
Wed, 18 Apr 2018 13:15:00
Scancell signs manufacturing agreement for its Moditope anti-cancer platform
The AIM-listed firm said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system
Tue, 03 Apr 2018 05:40:00